Reporting from: – American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego – San Antonio Breast Cancer Symposium, December 8-11, 2004 – Gastrointestinal Canc
Reporting from:
– American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego
– San Antonio Breast Cancer Symposium, December 8-11, 2004
– Gastrointestinal Cancers Symposium, January 27-29, 2005, Hollywood, Florida
In this edition:
Responses to a new drug, BMS 354 825, have been achieved among patients whose chronic myeloid leukemia has relapsed after treatment with
imatinib, said Charles Sawyers at the ASH conference. Early results with
another imatinib alternative, AMN 107, are also promising, as discussed by
Francis Giles.
The ATAC trial (Arimidex and Tamoxifen: Alone or in Combination), designed to find out whether it’s better to have five years of single-agent tamoxifen or single-agent anastrazole for breast cancer, now has 68 months of follow-up. Tony Howell presented data in San Antonio showing a superiority for aromatase inhibition in postmenopausal women.
The benefit of adding bevacizumab targeted therapy to cytotoxic regimens
among pretreated patients with advanced colorectal cancer was announced at the Gastrointestinal Cancers Symposium. Bruce Giantonio presented results from the Eastern Cooperative Oncology Group study in which bevacizumab was added to FOLFOX chemotherapy and produced an improvement in survival.
….